[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 29 of about 29
1. Lin PP, Jaffe N, Herzog CE, Costelloe CM, Deavers MT, Kelly JS, Patel SR, Madewell JE, Lewis VO, Cannon CP, Benjamin RS, Yasko AW: Chemotherapy response is an important predictor of local recurrence in Ewing sarcoma. Cancer; 2007 Feb 1;109(3):603-11
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy response is an important predictor of local recurrence in Ewing sarcoma.
  • The purpose of the study was to determine the factors that predict local recurrence after surgical treatment of the primary tumor.
  • Response to preoperative chemotherapy was determined by detailed specimen mapping.
  • Patients with a good response to chemotherapy (> or = 90% tumor necrosis), had superior LRFS at 5 years (86% vs 51%, P = .015).
  • The LRFS at 5 years was 50% for the chest wall, 74% for pelvic/scapular, and 86% for extremity tumors (P = .083).
  • A critical analysis of minimal surgical margin based on preoperative magnetic resonance imaging (MRI) and computed tomography (CT) scans also failed to reveal an association between margin and local recurrence.
  • In multivariate analysis, the 2 independent predictors of local recurrence were histological response to chemotherapy and central site of disease.
  • An important predictive factor is the response to chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / drug therapy. Neoplasm Recurrence, Local / diagnosis. Sarcoma, Ewing / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Infant. Male. Middle Aged. Neoplasm Staging. Prognosis. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 American Cancer Society.
  • (PMID = 17177205.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


2. Vale CL, Tierney JF, Davidson SE, Drinkwater KJ, Symonds P: Substantial improvement in UK cervical cancer survival with chemoradiotherapy: results of a Royal College of Radiologists' audit. Clin Oncol (R Coll Radiol); 2010 Sep;22(7):590-601
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Survival, recurrence and late complications were assessed for patients grouped according to radical treatment received (radiotherapy, chemoradiotherapy, postoperative radiotherapy or chemoradiotherapy) and non-radical treatment.
  • Overall 5-year survival was 56% (any radical treatment); 44% (radical radiotherapy); 55% (chemoradiotherapy) and 71% (surgery with postoperative radiotherapy).
  • Cox regression showed that survival was significantly better for patients receiving chemoradiotherapy (hazard ratio=0.77, 95% confidence interval 0.60-0.98; P=0.037) compared with those receiving radiotherapy taking age, stage, pelvic node involvement and treatment delay into account.
  • Although complications continued to develop up to 7 years after treatment for those receiving chemoradiotherapy, there was no apparent increase in overall late complications compared with radiotherapy alone when other factors were taken into account (hazard ratio=0.94, 95% confidence interval 0.71-1.245; P=0.667).
  • DISCUSSION: The addition of chemotherapy to radiotherapy seems to have improved survival compared with radiotherapy alone for women treated in 2001-2002, without an apparent rise in late treatment complications.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brachytherapy. Medical Audit. Survivors. Uterine Cervical Neoplasms / mortality. Uterine Cervical Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Bone Neoplasms / mortality. Bone Neoplasms / secondary. Bone Neoplasms / therapy. Combined Modality Therapy. Female. Humans. Liver Neoplasms / mortality. Liver Neoplasms / secondary. Liver Neoplasms / therapy. Lung Neoplasms / mortality. Lung Neoplasms / secondary. Lung Neoplasms / therapy. Lymphatic Metastasis. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / therapy. Neoplasm Staging. Pelvic Neoplasms / etiology. Pelvic Neoplasms / pathology. Radiation Oncology. Radiotherapy Dosage. Survival Rate. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.
  • [Cites] Clin Oncol (R Coll Radiol). 2000;12(6):347-53 [11202086.001]
  • [Cites] Radiother Oncol. 2003 Nov;69(2):195-200 [14643958.001]
  • [Cites] Radiother Oncol. 1993 Mar;26(3):195-202 [8316648.001]
  • [Cites] Int J Cancer. 1995 Nov 3;63(3):324-9 [7591225.001]
  • [Cites] N Engl J Med. 1999 Apr 15;340(15):1137-43 [10202164.001]
  • [Cites] N Engl J Med. 1999 Apr 15;340(15):1144-53 [10202165.001]
  • [Cites] N Engl J Med. 1999 Apr 15;340(15):1154-61 [10202166.001]
  • [Cites] BMJ. 1999 Apr 3;318(7188):904-8 [10102852.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1339-48 [10334517.001]
  • [Cites] Int J Gynaecol Obstet. 2006 Nov;95 Suppl 1:S43-103 [17161167.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Nov 15;69(4):1218-21 [17689027.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2008 Jun;20(5):358-64 [18395427.001]
  • [Cites] J Clin Oncol. 2008 Dec 10;26(35):5802-12 [19001332.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2009 Feb;21(1):49-55 [19081712.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2009 Sep;21(7):566-72 [19581073.001]
  • [CommentIn] Clin Oncol (R Coll Radiol). 2010 Sep;22(7):586-7 [20584594.001]
  • (PMID = 20594810.001).
  • [ISSN] 1433-2981
  • [Journal-full-title] Clinical oncology (Royal College of Radiologists (Great Britain))
  • [ISO-abbreviation] Clin Oncol (R Coll Radiol)
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MC/ U122861323; United Kingdom / Medical Research Council / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2941040
  •  go-up   go-down


3. Segawa N, Azuma H, Takahara K, Hamada S, Kotake Y, Tsuji M, Katsuokai Y: [Port-site metastasis after retroperitoneoscopy-assisted nephroureterectomy and cystectomy for bladder cancer invading the ureter: a case report]. Hinyokika Kiyo; 2008 Jan;54(1):13-6
MedlinePlus Health Information. consumer health - Endoscopy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The diagnosis was invasive bladder cancer with bone metastasis.
  • He received two courses of chemotherapy (methotrexate, vinblastine, adriamycin, cisplatin), and this resulted in resolution of the bone metastases.
  • Two months later, abdominal and pelvic computed tomography showed a bladder tumor invading the left lower ureter with hydronephrosis.
  • The patient was unable to undergo systemic chemotherapy because of renal dysfunction.
  • Four months later, a lateral abdominal wall tumor was found at a port-site, and needle biopsy confirmed this to be metastatic urothelial carcinoma.
  • [MeSH-major] Abdominal Neoplasms / secondary. Carcinoma / surgery. Cystectomy. Endoscopy. Neoplasm Invasiveness. Neoplasm Seeding. Nephrectomy. Ureter / surgery. Ureteral Neoplasms / surgery. Urinary Bladder Neoplasms / surgery

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18260354.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


Advertisement
4. Hamanishi J, Higuchi T, Mandai M, Fukuhara K, An M, Nakayama T, Takakura K, Fujii S: Intractable recurrent cervical cancer with pelvic bone involvement successfully treated with external hemipelvectomy. J Obstet Gynaecol Res; 2008 Feb;34(1):112-6
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intractable recurrent cervical cancer with pelvic bone involvement successfully treated with external hemipelvectomy.
  • The indication of external hemipelvectomy for lateral recurrent cervical cancer involving the pelvic bone is controversial.
  • A large multicystic recurrent tumor was identified in the right obturator region.
  • After chemotherapy and chemoradiation, the tumor regressed, but soon relapsed.
  • The patient's symptoms flared and the tumor was enlarged involving the right iliac bone.
  • We performed right external hemipelvectomy with amputation of the right lower extremity, right iliac wing and ischiopubic bone.
  • In selected cases of intractable lateral recurrent cervical cancer with pelvic bone involvement, relief from tumor-related pain and a possibility of prolonged survival can be expected by external hemipelvectomy.
  • [MeSH-major] Carcinoma, Squamous Cell / diagnosis. Neoplasm Recurrence, Local / diagnosis. Pelvic Bones / surgery. Pelvic Neoplasms / diagnosis. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Adult. Combined Modality Therapy. Conization. Diagnosis, Differential. Female. Humans. Neoplasm Metastasis


5. Paramelle O, Croué A, Dupré F, Rialland X, Saint-André JP: [Pelvic malignant ectomesenchymoma: a case report]. Ann Pathol; 2001 Aug;21(4):344-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pelvic malignant ectomesenchymoma: a case report].
  • We report the case of a 19 month old boy referred to our institution because of a pelvic tumor initially identified as an embryonal rhabdomyosarcoma and treated with surgery and chemotherapy.
  • Eight years after the initial surgery, a local tumor recurrence with bone metastasis was found.
  • This double differentiation was retrospectively found in the initial tumor, then allowing the diagnosis of malignant ectomesenchymoma also called gangliorhabdomyosarcoma.
  • This rare tumor, occurring mainly during childhood, is composed of neuroblasts and / or ganglion cells and of malignant mesenchymal cells (usually rhabdomyosarcomatous cells).
  • [MeSH-major] Mesenchymoma / pathology. Pelvic Neoplasms / pathology. Rhabdomyosarcoma / pathology
  • [MeSH-minor] Bone Neoplasms / secondary. Cell Differentiation. Diagnosis, Differential. Fatal Outcome. Femoral Neoplasms / secondary. Ganglia / pathology. Humans. Immunohistochemistry. Infant. Male. Neoplasm Recurrence, Local. Neurons / pathology. Rhabdomyosarcoma, Embryonal

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11685134.001).
  • [ISSN] 0242-6498
  • [Journal-full-title] Annales de pathologie
  • [ISO-abbreviation] Ann Pathol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


6. Berrebi O, Steiner C, Keller A, Rougemont AL, Ratib O: F-18 fluorodeoxyglucose (FDG) PET in the diagnosis of malignant transformation of fibrous dysplasia in the pelvic bones. Clin Nucl Med; 2008 Jul;33(7):469-71
Genetic Alliance. consumer health - Fibrous Dysplasia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] F-18 fluorodeoxyglucose (FDG) PET in the diagnosis of malignant transformation of fibrous dysplasia in the pelvic bones.
  • Fibrous dysplasia (FD) is a benign dysplastic pathology of bone-forming mesenchymal cells, resulting in replacement of trabecular bone by abnormal fibrous and immature osseous tissue.
  • We report the case of a 59-year-old woman with monostotic FD of the left ischium, known for over 30 years, who developed sarcomatous transformation in a low-grade spindle-cell sarcoma.
  • The value of F-18 fluorodeoxyglucose positron emission tomography in the early diagnosis of malignant transformation, the evaluation of distant metastasis, as well as monitoring the efficacy of chemotherapy are discussed.
  • [MeSH-major] Fibrous Dysplasia of Bone / diagnosis. Fibrous Dysplasia of Bone / radionuclide imaging. Fluorodeoxyglucose F18. Pelvis / radionuclide imaging. Radiopharmaceuticals
  • [MeSH-minor] Bone and Bones / radionuclide imaging. Cell Proliferation. Cell Transformation, Neoplastic. Fatal Outcome. Female. Humans. Middle Aged. Neoplasm Metastasis. Positron-Emission Tomography / methods. Sarcoma / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18580231.001).
  • [ISSN] 1536-0229
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Databank-accession-numbers] OMIM/ 174800
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


7. Ding Y, Niu XH, Zhang Q, Ma K, Liu WF: [The surgical treatment of primary malignant bone tumors of pelvis]. Zhonghua Wai Ke Za Zhi; 2008 Jun 15;46(12):886-90
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The surgical treatment of primary malignant bone tumors of pelvis].
  • OBJECTIVE: To evaluate the surgical treatment effect of primary malignant pelvic bone tumors.
  • METHODS: Retrospective study was carried out in 79 patients with primary malignant pelvic bone tumors treated surgically and followed up regularly between October 1992 and July 2007.
  • According to the preoperative diagnosis and the effect of chemotherapy, different methods of tumor resection and reconstruction were applied respectively.
  • The mean time of follow-up was 28.6 months (range, 0-183 months).
  • The minimum follow-up time in survival patients was 4 months.
  • In 14 patients developed postoperative distant metastasis, 12 in local recurrence group which incidence was 48.0%, compared to 2 in no-recurrence group which incidence was 3.7%, and the difference was significant (P = 0.000).
  • CONCLUSIONS: Wide surgical margin is essential for successful resection of primary malignant pelvic bone tumors.
  • [MeSH-major] Bone Neoplasms / surgery. Pelvic Bones
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19035144.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


8. Mylonas I, Briese V, Vogt-Weber B, Friese K: Complete bilateral crossed ureteral duplication observed during a radical hysterectomy with pelvic lymphadenectomy for ovarian cancer. A case report. Arch Gynecol Obstet; 2003 Feb;267(4):250-1
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete bilateral crossed ureteral duplication observed during a radical hysterectomy with pelvic lymphadenectomy for ovarian cancer. A case report.
  • We report the case of a patient diagnosed with ovarian cancer, in which complete crossed bilateral ureteral duplication was observed during a planned radical hysterectomy with pelvic lymphadenectomy operation.
  • Although bilateral ureteral duplication is an even rarer malformation than unilateral, it should be always considered as a differential diagnosis.
  • [MeSH-major] Ovarian Neoplasms / diagnosis. Ureter / abnormalities
  • [MeSH-minor] Acetabulum. Bone Neoplasms / diagnosis. Bone Neoplasms / drug therapy. Bone Neoplasms / radiography. Bone Neoplasms / secondary. Bone Neoplasms / surgery. Bone Neoplasms / ultrasonography. Fatal Outcome. Female. Femur. Humans. Hysterectomy. Liver Neoplasms / diagnosis. Liver Neoplasms / drug therapy. Liver Neoplasms / pathology. Liver Neoplasms / radiography. Liver Neoplasms / surgery. Liver Neoplasms / ultrasonography. Lymph Node Excision. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Pelvis / surgery. Sacrum

  • Genetic Alliance. consumer health - Ovarian cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12592431.001).
  • [ISSN] 0932-0067
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


9. Mohile SG, Schleicher L, Petrylak DP: Treatment of metastatic urachal carcinoma in an elderly woman. Nat Clin Pract Oncol; 2008 Jan;5(1):55-8
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of metastatic urachal carcinoma in an elderly woman.
  • On physical examination, she had a palpable pelvic mass.
  • Imaging revealed a large pelvic mass situated on the dome of the bladder, extending from the urachus, without evidence of other sites of metastases.
  • No adjuvant therapy was administered.
  • Repeat imaging obtained 3 months after resection revealed a large left pelvic mass consistent with recurrence.
  • INVESTIGATIONS: Physical examination, pelvic and complete lymph-node examination, laboratory tests, urine analysis, CT scan of the abdomen and pelvis, chest X-ray, bone scan, cystoscopy, histologic examination of tumor morphology, and MRI of the abdomen and pelvis.
  • DIAGNOSIS: Metastatic urachal adenocarcinoma.
  • MANAGEMENT: Surgical excision combined with cystectomy and pelvic lympadenectomy, chemotherapy with 5-fluorouracil, leucovorin, and irinotecan.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Signet Ring Cell / secondary. Cystectomy. Lymph Node Excision. Pelvic Neoplasms / secondary. Urachus. Urinary Bladder Neoplasms / surgery
  • [MeSH-minor] Aged. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Combined Modality Therapy. Diagnosis, Differential. Female. Fluorouracil / administration & dosage. Humans. Leucovorin / administration & dosage. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / radiotherapy. Neoplasm Recurrence, Local / surgery. Radiotherapy, Adjuvant

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18097457.001).
  • [ISSN] 1743-4262
  • [Journal-full-title] Nature clinical practice. Oncology
  • [ISO-abbreviation] Nat Clin Pract Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 7673326042 / irinotecan; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin; IFL protocol
  •  go-up   go-down


10. Sheng XG, Zhang XL, Fu Z, Li HQ, Li QS, Ma ZF, Li DP, Chen ZY: [Value of positron emission tomography-CT imaging combined with continual detection of CA125 in serum for diagnosis of early asymptomatic recurrence of epithelial ovarian carcinoma]. Zhonghua Fu Chan Ke Za Zhi; 2007 Jul;42(7):460-3
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Value of positron emission tomography-CT imaging combined with continual detection of CA125 in serum for diagnosis of early asymptomatic recurrence of epithelial ovarian carcinoma].
  • OBJECTIVE: To evaluate the value of positron emission tomography (PET)-CT imaging combined with continual detection of CA125 in serum for diagnosis of early recurrent ovarian epithelial carcinoma.
  • METHODS: Twenty six patients received PET-CT imaging, who were all diagnosed as primary epithelial ovarian cancer of stage II - IV and had complete remission after cytoreductive surgery and multiple courses of chemotherapy in Shandong Provincial Cancer Hospital.
  • After a steady period, all patients experienced progressive rising of CA125 values 3 times in 2 months.
  • (1) Of 26 patients, the value of CA125 was more than 35 kU/L in 17, and in 14 of 17, pelvic or abdominal cavity recurrence was diagnosed by CT and PET-CT, and 4 showed simultaneously distant metastasis on PET-CT.
  • In the remaining 3 patients of which CT findings were negative, 2 had pelvic and abdominal cavity recurrence, and one had bone metastasis on PET-CT.
  • Of 9 patients with progressive rising CA125 levels but the value was less than cut-off (< 35 kU/L), only 3 were found recurrence in pelvic and abdominal cavity by CT; however, all showed at least one suspicious recurrent or metastasis lesion on PET-CT. (2) Of 10 patients who received re-cytoreductive surgery, the value of CA125 was higher than cut-off in 6, and less in 4.
  • Four were diagnosed as recurrence by CT and PET-CT, and 6 were only confirmed by PET-CT with 1 - 5 abnormal metabolic lesions found. (3) In 10 patients who received re-cytoreductive surgery, all suspicious positive lesions identified by CT were proved recurrence or metastasis by pathology, and abnormal metabolic lesions showed by PET-CT were all confirmed to be metastasis by postoperative pathology. (4) After 1 month of re-cytoreductive surgery, the value declined by 3.2 fold in 4 whose CA125 value was less than cut-off; in another 6, the value declined to less than cut-off in 4, and in one after 2 cycles of re-chemotherapy, but the remaining one patient had persistent CA125 values more than cut-off.
  • Combined with the continual detection of CA125, a high accuracy of diagnosis can be achieved.
  • So it is an effective means for diagnosis of early recurrent ovarian cancer.
  • [MeSH-major] CA-125 Antigen / blood. Neoplasm Recurrence, Local / diagnosis. Ovarian Neoplasms / diagnosis. Ovary / pathology. Positron-Emission Tomography / methods
  • [MeSH-minor] Adult. Aged. Female. Humans. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Prognosis. Reproducibility of Results. Sensitivity and Specificity. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17961335.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / CA-125 Antigen
  •  go-up   go-down


11. Katsumoto Y, Aritake N, Yamamoto H: [Multimodal therapy for juvenile advanced rectal carcinoma]. Gan To Kagaku Ryoho; 2008 Nov;35(12):2135-7
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Multimodal therapy for juvenile advanced rectal carcinoma].
  • A 37-year-old male with locally advanced rectal carcinoma and liver metastasis was treated by multimodal therapy.
  • After his general condition was recovered, the patient received systemic chemotherapy with mFOLFOX6 (6 courses) and whole pelvic irradiation (40 Gy).
  • The rectal tumor showed a reduction in size, total pelvic evisceration combined with reconstruction of ileal conduit and rectus abdominus myocutaneous (RAM) flap were performed.
  • He was followed by 7 courses of systemic chemotherapy with mFOLFOX6 and bevacizumab.
  • After partial hepatic resection, he was followed by systemic chemotherapy with FOLFIRI and bevacizumab as an outpatient.
  • Recent studies for outcomes in young colorectal carcinoma patients showed that the poor prognosis was not caused by its proper aggressiveness in biologic behavior but just the late diagnosis.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Rectal Neoplasms / drug therapy. Rectal Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Bone Neoplasms / drug therapy. Bone Neoplasms / secondary. Bone Neoplasms / surgery. Combined Modality Therapy. Humans. Liver Neoplasms / drug therapy. Liver Neoplasms / radiography. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Male. Neoplasm Staging. Surveys and Questionnaires. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19106548.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


12. Grimer RJ, Gosheger G, Taminiau A, Biau D, Matejovsky Z, Kollender Y, San-Julian M, Gherlinzoni F, Ferrari C: Dedifferentiated chondrosarcoma: prognostic factors and outcome from a European group. Eur J Cancer; 2007 Sep;43(14):2060-5
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In particular there remains uncertainty about the value of chemotherapy for this condition.
  • We obtained data on 337 patients from nine European centres with this rare condition, with details on patients, treatment and outcome which were then analysed in an attempt to identify prognostic features.
  • The most common sites were the femur and pelvis.
  • Twenty-nine percent of patients with a long bone tumour had a pathological fracture.
  • 71 patients (21%) had metastases at the time of diagnosis and these patients had a median survival of 5 months with a 10% chance of survival at 2 years.
  • For the 266 patients without metastases at diagnosis, 254 underwent surgery with 79% having limb salvage.
  • Thirty-one percent of these 266 patients had chemotherapy with 47% of those under 60 receiving it.
  • In this group of 266 patients, overall survival was 28% at 10 years and poor prognostic factors were the presence of a pathological fracture at diagnosis, a pelvic location and increasing age.
  • We did not find that the histological subtype, size of the tumour or the use of chemotherapy significantly affected outcome.
  • Surgery with clear margins remains the principal treatment for this condition.
  • Further use of chemotherapy should be within a trial or treatment protocol.
  • [MeSH-major] Bone Neoplasms / mortality. Chondrosarcoma / mortality
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Europe / epidemiology. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Prognosis. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Chondrosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17720491.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


13. Oaknin A, Barretina MP, Morilla I: Muscle metastasis of low-grade endometrial carcinoma seven years after diagnosis: a case report. Eur J Gynaecol Oncol; 2010;31(1):114-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Muscle metastasis of low-grade endometrial carcinoma seven years after diagnosis: a case report.
  • After four years she had local relapse without response to chemoradiation, requiring pelvic exanteration.
  • Three years later she was diagnosed with a deltoid muscle metastasis confirmed histologically and bone metastases.
  • After failing hormone therapy, chemotherapy was administered.
  • She died eight months after diagnosis of the bone and muscle metastases.
  • [MeSH-minor] Aged. Arm. Female. Humans. Muscle, Skeletal. Neoplasm Recurrence, Local

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20349796.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


14. Bruns J, Fiedler W, Werner M, Delling G: Dedifferentiated chondrosarcoma--a fatal disease. J Cancer Res Clin Oncol; 2005 Jun;131(6):333-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The mean age of the patients at diagnosis was 59.8 years.
  • In one out of three patients with a pelvic tumour resection was followed by implantation of a pelvic replacement; the other two patients received tumour resection with autologous stabilisation of the pelvis.
  • Adjuvant chemotherapy was given to five patients.
  • The mean survival time was 9.7 months.
  • DDCS is rare and is the primary malignant bone tumour with the worst prognosis.
  • Surgery is the most important procedure, although it is unclear whether a radical resection improves the long-term results.
  • Information regarding neoadjuvant and/or adjuvant therapy with chemotherapy is very limited.
  • [MeSH-major] Bone Neoplasms / mortality. Chondrosarcoma / mortality
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Differentiation. Chemotherapy, Adjuvant. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Prognosis. Survival Rate. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Chondrosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Oncol. 2001 Jun;12(6):859-64 [11484965.001]
  • [Cites] J Bone Joint Surg Br. 1979 Nov;61-B(4):395-400 [500746.001]
  • [Cites] J Pathol. 1999 Dec;189(4):454-62 [10629543.001]
  • [Cites] Am J Surg Pathol. 2000 Aug;24(8):1079-86 [10935648.001]
  • [Cites] Histopathology. 1998 Jul;33(1):11-9 [9726043.001]
  • [Cites] Cancer. 1986 Jul 15;58(2):287-98 [3521830.001]
  • [Cites] Clin Orthop Relat Res. 1977 Jan-Feb;(122):157-64 [837602.001]
  • [Cites] Cancer. 1984 Jun 15;53(12):2674-8 [6722725.001]
  • [Cites] J Pathol. 1999 Dec;189(4):445-7 [10629541.001]
  • [Cites] Ital J Orthop Traumatol. 1979 Dec;5(3):331-41 [553917.001]
  • [Cites] Hum Pathol. 1982 Jan;13(1):36-40 [7076193.001]
  • [Cites] J Bone Joint Surg Am. 1974 Mar;56(2):285-96 [4452687.001]
  • [Cites] J Bone Joint Surg Br. 2000 Jan;82(1):55-61 [10697315.001]
  • [Cites] J Bone Joint Surg Am. 1991 Feb;73(2):294-300 [1993724.001]
  • [Cites] Clin Orthop Relat Res. 1980 Nov-Dec;(153):106-20 [7449206.001]
  • [Cites] J Bone Joint Surg Am. 1988 Jan;70(1):60-9 [3335575.001]
  • [Cites] Hum Pathol. 1985 Mar;16(3):318-20 [3882551.001]
  • [Cites] J Bone Joint Surg Am. 1986 Oct;68(8):1197-205 [3021775.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1991;418(5):419-25 [2035255.001]
  • [Cites] Cancer. 1986 Jul 15;58(2):278-86 [3719521.001]
  • [Cites] Cancer. 1971 Aug;28(2):461-6 [5566365.001]
  • [Cites] Skeletal Radiol. 1998 Oct;27(10 ):569-73 [9840394.001]
  • [Cites] J Bone Joint Surg Br. 1979 Aug;61-B(3):366-72 [225333.001]
  • [Cites] Pediatr Radiol. 1995 Nov;25 Suppl 1:S140-2 [8577508.001]
  • [Cites] Skeletal Radiol. 1995 Aug;24(6):409-16 [7481896.001]
  • [Cites] Cancer. 1976 Mar;37(3):1365-75 [1260656.001]
  • [Cites] Virchows Arch. 2000 May;436(5):494-7 [10881744.001]
  • (PMID = 15785935.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


15. Ebelin M, Missenard G, Nordin JY: [Iatrogenic tumor metastasis to the pelvis after treatment for hand osteosarcoma. A case report]. Chir Main; 2000 Nov;19(5):272-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Iatrogenic tumor metastasis to the pelvis after treatment for hand osteosarcoma. A case report].
  • This was first treated by curettage, iliac bone graft and internal fixation, without any complementary investigation being carried out, i.e., no preliminary biopsy and histological diagnosis were made.
  • Moreover, the definitive diagnosis was only made four months later, when biopsy findings confirmed the presence of an osteosarcoma.
  • After neoadjuvant chemotherapy, an en-bloc resection of the second metatarsal and the trapezoid bone was carried out.
  • However, nearly a year later the discovery of a large tumor mass at the site where the iliac bone graft was originally taken necessitated resection of the hemi-pelvis, with chemotherapy prior to resection and radiotherapy following surgery.
  • Unfortunately, this salvage procedure did not limit the spread of the disease, and subsequent pulmonary and vertebral metastases were found, leading to the death of the patient three years after the initial fracture.
  • [MeSH-major] Bone Neoplasms / pathology. Bone Transplantation / adverse effects. Curettage / adverse effects. Fracture Fixation, Internal / adverse effects. Fractures, Spontaneous / etiology. Hand Injuries / etiology. Iatrogenic Disease. Ilium / transplantation. Metacarpus / injuries. Neoplasm Seeding. Osteosarcoma / secondary. Pelvic Bones
  • [MeSH-minor] Biopsy. Combined Modality Therapy. Fatal Outcome. Hemipelvectomy. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Prognosis. Salvage Therapy. Tomography, X-Ray Computed


16. Aydinli U, Ozturk C, Yalcinkaya U, Tirelioglu O, Ersozlu S: Limb-sparing surgery for primary malignant tumours of the pelvis. Acta Orthop Belg; 2004 Oct;70(5):417-22
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Limb-sparing surgery for primary malignant tumours of the pelvis.
  • Treatment of malignant tumours of the pelvis represents one of the most difficult problems in musculoskeletal oncology.
  • The aim of this paper is to present our results in 16 cases of primary malignant pelvic tumours following resection only or following reconstruction with autogenous or allogenous bone grafts without using megaprostheses, and to assess the possibility to restore acceptable function with autogenous or allogenous bone grafts while avoiding the high risks of massive endoprostheses.
  • Wound complication was the most common complication in our series, with 10 patients requiring additional treatment in the form of local surgical debridement, appropriate multi-drug antimicrobial therapy and wound care.
  • Secondary pelvic reconstruction was performed in two patients with chondrosarcoma, due to local recurrence.
  • Major blood loss and long operation time, aggressive radical surgery due to the frequent delay in diagnosis, and wound complications after surgery are important points that should be considered in the treatment of primary malignant pelvic tumours.
  • [MeSH-major] Bone Neoplasms / surgery. Bone Transplantation. Hemipelvectomy / methods. Limb Salvage. Pelvic Bones. Sarcoma / surgery
  • [MeSH-minor] Adult. Angiography. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Staging. Prognosis. Reconstructive Surgical Procedures / methods. Retrospective Studies. Risk Assessment. Sampling Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Bone Grafts.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15587029.001).
  • [ISSN] 0001-6462
  • [Journal-full-title] Acta orthopaedica Belgica
  • [ISO-abbreviation] Acta Orthop Belg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


17. Sucato DJ, Rougraff B, McGrath BE, Sizinski J, Davis M, Papandonatos G, Green D, Szarzanowicz T, Mindell ER: Ewing's sarcoma of the pelvis. Long-term survival and functional outcome. Clin Orthop Relat Res; 2000 Apr;(373):193-201
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ewing's sarcoma of the pelvis. Long-term survival and functional outcome.
  • Fifty patients with Ewing's sarcoma of the pelvis were treated using a multidisciplinary approach; followup of surviving patients averaged 137 months (range, 40-276 months).
  • The addition of surgical resection to the multidisciplinary treatment for all patients was associated with improved survival compared with survival of patients treated with chemotherapy and radiation therapy alone; the addition of surgery to the treatment regimen of 37 patients without metastases also was associated with improved survival.
  • There were no significant differences between the surgical and nonsurgical groups in terms of tumor size, stage of disease, patient age, duration of symptoms before diagnosis, or anatomic site.
  • Surgery was used more often in recently treated patients, but the year of diagnosis and treatment did not significantly affect overall survival, secondary to large confidence intervals.
  • The Short Form-36 and the Musculoskeletal Tumor Society functional evaluation instruments showed a superior level of function in the nonsurgical group, but this difference was not statistically significant.
  • There have been many advances in the treatment of patients with Ewing's sarcoma during the past 3 decades, resulting in improved survival for patients with Ewing's sarcoma of the pelvis.
  • [MeSH-major] Bone Neoplasms / surgery. Pelvic Bones / surgery. Postoperative Complications / mortality. Sarcoma, Ewing / surgery
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Follow-Up Studies. Humans. Male. Neoplasm Staging. Survival Rate

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10810477.001).
  • [ISSN] 0009-921X
  • [Journal-full-title] Clinical orthopaedics and related research
  • [ISO-abbreviation] Clin. Orthop. Relat. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


18. Bading S, Mössinger E, Rosenthal H, Länger F, Bastian L: [Osteosarcoma of the pelvisTwo case reports and review of the literature]. Unfallchirurg; 2004 Jul;107(7):625-32
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Osteosarkome des SakrumsZwei Fallbeispiele und Literaturübersicht.
  • Primary malignant neoplasms of the bone are rare.
  • One of the most common bone tumors is osteosarcoma, most often localized in the metaphysis of adolescent long bones.
  • Primary bone sarcomas of the pelvis are usually recognized after they have grown to a considerable size.
  • Osteosarcoma patients from Germany, Austria, and Switzerland are treated by neoadjuvant chemotherapy combined with complete surgical excision according to the Cooperative Osteosarcoma Study Group (COSS).
  • Based on a review of the literature, diagnosis, treatment, and complications of two cases of sacrum osteosarcoma are introduced.
  • [MeSH-minor] Adult. Biopsy. Disease Progression. Female. Follow-Up Studies. Humans. Male. Neoplasm Recurrence, Local / diagnostic imaging. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Pelvic Bones / diagnostic imaging. Pelvic Bones / pathology. Postoperative Complications / diagnostic imaging. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Osteosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2002 Jan 1;20(1):189-96 [11773169.001]
  • [Cites] Clin Orthop Relat Res. 1991 Sep;(270):79-86 [1715820.001]
  • [Cites] Clin Orthop Relat Res. 2004 Sep;(426):219-25 [15346077.001]
  • [Cites] J Clin Oncol. 2002 Feb 1;20(3):776-90 [11821461.001]
  • [Cites] Chirurg. 2002 Dec;73(12):1162-9 [12491044.001]
  • [Cites] Nuklearmedizin. 1999;38(8):337-40 [10615669.001]
  • [Cites] Acta Oncol. 1996;35(3):381-4 [8679270.001]
  • [Cites] Clin Orthop Relat Res. 1998 Mar;(348):196-207 [9553553.001]
  • [Cites] J Bone Joint Surg Am. 1967 Jan;49(1):101-10 [5225072.001]
  • [Cites] J Clin Oncol. 1984 Jun;2(6):617-24 [6202851.001]
  • [Cites] Unfallchirurg. 2003 Nov;106(11):956-62 [14634740.001]
  • [Cites] Langenbecks Arch Chir. 1982;358:403-8 [7169888.001]
  • [Cites] Radiol Clin North Am. 1993 Mar;31(2):261-78 [8446749.001]
  • [Cites] J Bone Joint Surg Br. 1999 Sep;81(5):796-802 [10530839.001]
  • [Cites] J Bone Joint Surg Br. 1973 Feb;55(1):189-92 [4511937.001]
  • [Cites] Clin Orthop Relat Res. 1991 Sep;(270):4-7 [1884556.001]
  • [Cites] Pathologe. 1983 May;4(3):135-41 [6576329.001]
  • (PMID = 15060775.001).
  • [ISSN] 0177-5537
  • [Journal-full-title] Der Unfallchirurg
  • [ISO-abbreviation] Unfallchirurg
  • [Language] ger
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


19. Lee JA, Huh SJ, Oh D, Bae DS: Osteoradionecrosis after three-dimensional conformal radiotherapy for recurrent cervical cancer presenting as a progressive osteolytic lesion. Ann Nucl Med; 2008 Feb;22(2):139-41
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Osteoradionecrosis (ORN) of the pelvic bone presenting as a progressive osteolytic lesion, following three-dimensional conformal radiotherapy (3DCRT) with concurrent chemotherapy, is a clinical diagnostic challenge that must be differentiated from an osseous metastasis.
  • We report on a case with an unusual presentation of ORN mimicking bony metastasis that should be taken note of by physicians.
  • A 46-year-old woman who had recurrent cervical cancer in the right pelvic sidewall underwent concurrent salvage chemoradiotherapy.
  • She received 63 Gy 3DCRT.
  • At 22 months, post-RT, an asymptomatic but enlarging osseous defect in the right ilium, located within the area covered by a 95% isodose line, was demonstrated on pelvic computed tomography (CT).
  • ORN was confirmed by whole-body [18F] fluoro-2-deoxy-d-glucose (FDG)-positron emission tomography (PET) CT scan and CT-guided bone biopsy.
  • A localized, growing ORN of pelvic bone after high-dose 3DCRT is an uncommon late complication.
  • Differential diagnosis between ORN and bony metastasis may be possible with low FDG uptake of ORN on PET-CT scans.
  • [MeSH-major] Bone Neoplasms / radionuclide imaging. Carcinoma, Squamous Cell / pathology. Neoplasm Recurrence, Local / radiotherapy. Osteolysis / pathology. Osteolysis / radionuclide imaging. Osteoradionecrosis / radionuclide imaging. Radiotherapy, Conformal / adverse effects. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Chemotherapy, Adjuvant / adverse effects. Diagnosis, Differential. Female. Fluorodeoxyglucose F18 / pharmacokinetics. Humans. Hysterectomy. Ilium / pathology. Middle Aged. Positron-Emission Tomography. Salvage Therapy / adverse effects. Tomography, X-Ray Computed. Whole Body Imaging


20. Burdach S, van Kaick B, Laws HJ, Ahrens S, Haase R, Körholz D, Pape H, Dunst J, Kahn T, Willers R, Engel B, Dirksen U, Kramm C, Nürnberger W, Heyll A, Ladenstein R, Gadner H, Jürgens H, Go el U: Allogeneic and autologous stem-cell transplantation in advanced Ewing tumors. An update after long-term follow-up from two centers of the European Intergroup study EICESS. Stem-Cell Transplant Programs at Düsseldorf University Medical Center, Germany and St. Anna Kinderspital, Vienna, Austria. Ann Oncol; 2000 Nov;11(11):1451-62
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In order to evaluate a possible therapeutic benefit after allogeneic SCT in patients with advanced Ewing tumors (AET), we compared outcome after autologous and allogeneic stem-cell transplantation (SCT).
  • All patients underwent remission induction chemotherapy and local treatment before myeloablative therapy.
  • Seventeen of thirty-six patients had multifocal primary Ewing's tumor, eighteen of thirty-six had early, multiple or multifocal relapse, one of thirty-six patients had unifocal late relapse.
  • We analyzed the following risk factors, that could possibly influence the event-free survival (EFS): number of involved bones, degree of remission at time of SCT, type of graft, indication for SCT, bone marrow infiltration, bone with concomitant lung disease, age at time of diagnosis, pelvic involvement, involved compartment radiation, histopathological diagnosis.
  • Eighteen of thirty-six patients suffered relapse or died of disease, nine of thirty-six died of treatment related toxicity (DOC).
  • Age > or = 17 years at initial diagnosis (P < 0.005) significantly deteriorated outcome.
  • According to the type of graft, EFS was 0.25 +/- 0.08 after autologous and 0.20 +/- 0.13 after allogeneic SCT.
  • The patient group was to small to analyze for a possible graft-versus-tumor effect.

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11142486.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunologic Factors; 0 / Interleukin-2
  • [Number-of-references] 56
  •  go-up   go-down


21. Kushner BH, LaQuaglia MP, Kramer K, Cheung NK: Radically different treatment recommendations for newly diagnosed neuroblastoma: pitfalls in assessment of risk. J Pediatr Hematol Oncol; 2004 Jan;26(1):35-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radically different treatment recommendations for newly diagnosed neuroblastoma: pitfalls in assessment of risk.
  • Neuroblastoma risk stratification is based on stage, age, and biology and prescribes surgery for low-risk disease, moderate-dose chemotherapy for intermediate-risk disease, and maximal therapy (including myeloablative treatment with stem cell transplantation) for high-risk disease.
  • The first recommendations were for maximal therapy, but second opinions were radically different (ie, surgery alone).
  • Ages at diagnosis were 15 to 25 months.
  • All four patients did well without cytotoxic therapy (follow-up: 2 years 10 months plus to 4 years 8 months plus).
  • Patient 2 had retroperitoneal disease, without bone marrow involvement, but imaging studies showed lesions in vertebral bodies.
  • Biopsies of the latter showed no neuroblastoma and the primary tumor (with regional lymph nodes) was resected, changing stage from 4 to 2B.
  • Though initially deemed to be unresectable, the abdominal tumor was excised, changing the classification from high risk (stage 3 with unfavorable histopathology) to low risk (stage 1).
  • Patient 4 had a pelvic mass, with unfavorable histopathology, and bilateral inguinal lymph node involvement (stage 3); all soft tissue disease was resected.
  • The absence of cortical bone and extensive bone marrow metastatic involvement in a young neuroblastoma patient should cause a shift in attention to biologic prognostic markers.
  • Some patients classified as having high-risk neuroblastoma might actually do well with no cytotoxic therapy.
  • [MeSH-major] Health Planning Guidelines. Neuroblastoma / diagnosis. Neuroblastoma / surgery
  • [MeSH-minor] Biomarkers / analysis. Child, Preschool. Diagnostic Imaging. Female. Humans. Infant. Neoplasm Staging. Risk Assessment. Treatment Outcome

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14707711.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers
  •  go-up   go-down


22. Giannarini G, Kessler TM, Thoeny HC, Nguyen DP, Meissner C, Studer UE: Do patients benefit from routine follow-up to detect recurrences after radical cystectomy and ileal orthotopic bladder substitution? Eur Urol; 2010 Oct;58(4):486-94
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To determine whether diagnosis of asymptomatic recurrence after RC by routine follow-up investigations confers a survival benefit versus symptomatic recurrence.
  • DESIGN, SETTING, AND PARTICIPANTS: Retrospective analysis of 479 patients with nonmetastatic bladder TCC receiving no neoadjuvant chemotherapy/radiation therapy and prospectively followed with a standardised protocol for a median 4.3 yr (range: 0.3-20.9) after RC at an academic tertiary referral centre.
  • INTERVENTION: RC and extended pelvic lymph node dissection with ileal orthotopic bladder substitution.
  • The effects of age, nerve-sparing surgery, pathologic tumour stage, lymph node status, adjuvant chemotherapy, mode of recurrence diagnosis, and recurrence site on survival were assessed with multivariable Cox regression models.
  • Routine follow-up mostly detected lung metastases and urethral recurrences, while symptoms were predominantly the result of bone metastases and concomitant pelvic/distant recurrences.
  • Of these, 12 were successfully managed with urethra-sparing treatment, and 6 are still alive with no evidence of disease.
  • In multivariable analysis, mode of recurrence diagnosis and site of initial recurrence were the only independent predictors of CSS and OS.
  • Routine follow-up appears particularly effective in early detection of urethral CIS, which can be treated conservatively.
  • [MeSH-major] Carcinoma, Transitional Cell / diagnosis. Carcinoma, Transitional Cell / surgery. Cystectomy. Ileum / transplantation. Neoplasm Recurrence, Local / diagnosis. Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / surgery. Urinary Reservoirs, Continent
  • [MeSH-minor] Aged. Early Detection of Cancer. Female. Follow-Up Studies. Humans. Male. Middle Aged. Retrospective Studies. Time Factors

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 European Association of Urology. Published by Elsevier B.V. All rights reserved.
  • [CommentIn] Eur Urol. 2010 Oct;58(4):495-7 [20609511.001]
  • (PMID = 20541311.001).
  • [ISSN] 1873-7560
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


23. Sella A, Konichezky M, Flex D, Sulkes A, Baniel J: Low PSA metastatic androgen- independent prostate cancer. Eur Urol; 2000 Sep;38(3):250-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients received cisplatin-based therapy.
  • Specimens from the primary tumor were reviewed and neuroendocrine differentiation was determined with chromogranin-A and neuron-specific enolase immunocytochemical staining.
  • Metastases involved bone in 11 patients (61.1%) - 5 (27.7%) blastic, 2 (11.1%) lytic, and 4 (22.2%) combined - liver in 10 patients (55.5%), lymph nodes in 8 (44.4%), and lung in 6 (33.3%); solitary sites as orbit, skin and spleen were noted as well.
  • A prostatic pelvic mass was detected in 13 patients (72.2%).
  • Of the 12 patients who consented to chemotherapy, 8 (66.6%) achieved an objective response (95% CI, 34.
  • CONCLUSIONS: Progressive androgen-independent prostate cancer with low serum PSA is characterized by visceral metastases, high proportion of lytic bone disease, sensitivity to cisplatin-based chemotherapy, and histological features of small cell or poorly differentiated prostate cancer.
  • In this subgroup of patients, selection of the therapeutic approach can be based on clinical parameters.
  • The rise of the serum markers may aid in the diagnosis and follow-up of these patients.
  • [MeSH-minor] Androgens. Humans. Male. Neoplasm Metastasis. Neoplasm Staging. Prospective Studies


24. Escobar MA, Grosfeld JL, Powell RL, West KW, Scherer LR 3rd, Fallon RJ, Rescorla FJ: Long-term outcomes in patients with stage IV neuroblastoma. J Pediatr Surg; 2006 Feb;41(2):377-81
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Age at diagnosis was 29.1 +/- 31.7 months in survivors.
  • Primary tumor sites were adrenal (35), retroperitoneal (11), mediastinal (3), pelvic (2), and no primary with tumor metastases identified (1).
  • Treatment in survivors included surgery in 51 (75% [39/51] complete tumor resection [CTR]); chemotherapy, 50; radiation, 17; stem cell transplantation, 20; and bone marrow transplant, 1.
  • In nonsurvivors, 13 (25%) of 53 (P < < .0001) had CTR, 18 stem cell transplantation, and 12 bone marrow transplant.
  • Six patients had tumor recurrence but survived (mean, 9.3 +/- 8.3 years; range, 6 months-24 years).
  • Recurrence was local (1), distant (2), and both (3) and was treated by resection, chemotherapy, and radiation.
  • CONCLUSION: Only 34% of patients with stage IV NB survived despite aggressive multimodal therapy.
  • Forty-four percent of survivors experienced late morbidity, and tumor recurred in 6 (11.5%) of 52.
  • Patients should be monitored for tumor recurrence and long-term sequelae.
  • New methods of treatment are required to achieve better outcomes.
  • [MeSH-major] Neuroblastoma / pathology. Neuroblastoma / therapy. Survivors
  • [MeSH-minor] Child, Preschool. Female. Humans. Male. Neoplasm Staging. Retrospective Studies. Time Factors

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16481255.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Yoshida A, Edgar MA, Garcia J, Meyers PA, Morris CD, Panicek DM: Primary desmoplastic small round cell tumor of the femur. Skeletal Radiol; 2008 Sep;37(9):857-62
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary desmoplastic small round cell tumor of the femur.
  • Desmoplastic small round cell tumor (DSRCT) is a rare malignant neoplasm typically involving the abdominal cavity of a young male.
  • Extra-abdominal occurrence of this tumor is very rare.
  • Pulmonary metastases were present at initial staging studies, but no abdominal or pelvic lesion was present.
  • Despite chemotherapy and complete tumor excision, the patient developed progressive lung and bone metastases and died 3 years after initial presentation.
  • This is the second reported case of primary DSRCT of bone with genetic confirmation.
  • [MeSH-major] Diagnostic Imaging. Femoral Neoplasms / diagnosis. Sarcoma, Small Cell / diagnosis
  • [MeSH-minor] Biopsy. Child. Diagnosis, Differential. Fatal Outcome. Female. Humans. Lung Neoplasms / secondary. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Desmoplastic Small Round Cell Tumor.
  • MedlinePlus Health Information. consumer health - Diagnostic Imaging.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1998 Sep;16(9):3028-36 [9738572.001]
  • [Cites] Hum Pathol. 2000 May;31(5):532-8 [10836292.001]
  • [Cites] Am J Surg Pathol. 2002 Jul;26(7):823-35 [12131150.001]
  • [Cites] Am J Surg Pathol. 1999 Nov;23(11):1408-13 [10555010.001]
  • [Cites] Am J Surg Pathol. 2007 Mar;31(3):454-9 [17325488.001]
  • [Cites] Pediatr Pathol. 1989;9(2):177-83 [2473463.001]
  • [Cites] Am J Surg Pathol. 1999 Feb;23 (2):159-65 [9989842.001]
  • [Cites] Cancer Genet Cytogenet. 2005 Jan 15;156(2):167-71 [15642398.001]
  • [Cites] Cancer Res. 1994 Jun 1;54(11):2837-40 [8187063.001]
  • [Cites] Am J Surg Pathol. 1991 Jun;15(6):499-513 [1709557.001]
  • [Cites] J Clin Oncol. 2003 Sep 15;21(18):3423-30 [12972518.001]
  • (PMID = 18470511.001).
  • [ISSN] 0364-2348
  • [Journal-full-title] Skeletal radiology
  • [ISO-abbreviation] Skeletal Radiol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


26. Ok JH, Meyers FJ, Evans CP: Medical and surgical palliative care of patients with urological malignancies. J Urol; 2005 Oct;174(4 Pt 1):1177-82
MedlinePlus Health Information. consumer health - Palliative Care.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There are many effective medical and surgical palliative treatments, although few comprehensive guidelines have been published.
  • We reviewed the various palliative treatments available for the 3 most common urological malignancies, namely prostate cancer, bladder cancer and renal cancer.
  • RESULTS: Several effective treatments are available for the palliative care of patients with prostate, bladder or renal cancer.
  • CONCLUSIONS: Palliative care includes disease directed treatment as well as functional, psychosocial and spiritual support.
  • Disease directed therapy and palliative care should be provided simultaneously throughout illness.
  • Supportive care begins at initial diagnosis and it should be flexible to meet the changing needs of patients with cancer and their families.
  • [MeSH-major] Palliative Care. Urologic Neoplasms / therapy
  • [MeSH-minor] Algorithms. Bone Neoplasms / secondary. Carcinoma, Renal Cell / therapy. Hospices. Humans. Male. Neoplasm Invasiveness. Pelvic Pain / drug therapy. Prostatic Neoplasms / complications. Prostatic Neoplasms / pathology. Prostatic Neoplasms / therapy. Spinal Cord Compression / etiology. Spinal Cord Compression / surgery. Urinary Bladder Neck Obstruction / etiology. Urinary Bladder Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16145365.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 48
  •  go-up   go-down


27. Bar-Sever Z, Cohen IJ, Connolly LP, Horev G, Perri T, Treves T, Hardoff R: Tc-99m MIBI to evaluate children with Ewing's sarcoma. Clin Nucl Med; 2000 Jun;25(6):410-3
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Tc-99m MIBI has been used increasingly to evaluate benign and malignant tumors because of its tumor-seeking properties and ability to provide an imaging assessment of multiple-drug resistance.
  • All patients had imaging studies at diagnosis, and four had follow-up studies during or after therapy.
  • Scintigraphy was evaluated for Tc-99m MIBI uptake within the tumor and in metastases, which other imaging modalities had shown to be present in four patients.
  • Scintigraphic results were correlated with the clinical course in all patients and with tumor P-glycoprotein status in six patients.
  • RESULTS: Tc-99m MIBI accumulated in 6 of 9 primary tumors and did not accumulate in one recurrent tumor.
  • The presence or absence of Tc-99m MIBI uptake at diagnosis or after therapy carried no prognostic significance.
  • [MeSH-major] Bone Neoplasms / radionuclide imaging. Radiopharmaceuticals. Sarcoma, Ewing / radionuclide imaging. Technetium Tc 99m Sestamibi
  • [MeSH-minor] Adolescent. Adult. Child. Drug Resistance, Multiple. Drug Resistance, Neoplasm. Female. Femoral Neoplasms / radionuclide imaging. Femoral Neoplasms / therapy. Follow-Up Studies. Humans. Lung Neoplasms / radionuclide imaging. Lung Neoplasms / secondary. Male. Neoplasm Recurrence, Local / radionuclide imaging. P-Glycoprotein / analysis. Pelvic Bones / radionuclide imaging. Prognosis. Retrospective Studies

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10836685.001).
  • [ISSN] 0363-9762
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / P-Glycoprotein; 0 / Radiopharmaceuticals; 971Z4W1S09 / Technetium Tc 99m Sestamibi
  •  go-up   go-down


28. Rodríguez-Vázquez M, García-Arpa M, González-García J: Juvenile mycosis fungoides treated with bexarotene and PUVA. Int J Dermatol; 2007 Jan;46(1):99-102
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In follow-up, the patient developed two red-colored, mobile, well-delimited cutaneous nodules of 2.5 cm in diameter in the right hemithorax and lumbar area.
  • The lumbar nodule regressed spontaneously before treatment.
  • The clinical diagnosis was mycosis fungoides.
  • A bone marrow study and a thoraco-abdomino-pelvic scan were normal.
  • With the diagnosis of mycosis fungoides stage IVA (according to the TNM classification), treatment was initiated with psoralen plus ultraviolet light A (PUVA), three times a week, plus oral bexarotene at a dose of 300 mg/m2/day.
  • The parents were informed that this treatment was not approved for this age group and informed consent was obtained.
  • After 32 sessions of PUVA and 6 months of treatment with oral bexarotene, the skin patches regressed, except for the plaque on the left buttock and the nodule on the right hemithorax (Fig. 4).
  • Nevertheless, 5 months after discontinuation of oral treatment, the patient developed multiple, scaling, nonconfluent macules on the trunk and arms affecting almost 30% of the body surface area, which disappeared with the application of methylprednisolone aceponate.
  • [MeSH-major] Anticarcinogenic Agents / therapeutic use. Mycosis Fungoides / drug therapy. PUVA Therapy. Skin Neoplasms / drug therapy. Tetrahydronaphthalenes / therapeutic use
  • [MeSH-minor] Adolescent. Biopsy. Humans. Male. Neoplasm Staging

  • Genetic Alliance. consumer health - Mycosis fungoides.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17214731.001).
  • [ISSN] 0011-9059
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Tetrahydronaphthalenes; A61RXM4375 / bexarotene
  •  go-up   go-down


29. Nascimento AF, Fletcher CD: Spindle cell rhabdomyosarcoma in adults. Am J Surg Pathol; 2005 Aug;29(8):1106-13
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumor size varied from 1.5 to 35 cm (median, 6 cm).
  • Treatment modalities included surgery, chemotherapy, and radiation.
  • Two patients died of uncontrolled local disease 13 and 27 months after diagnosis; 4 were alive without disease at 12, 17, 24, and 102 months, including 1 patient with metastasis to 10 of 50 pelvic lymph nodes at presentation; 3 are alive with localized disease at 16, 17, and 19 months; and 1 was followed for 6 months and showed persistent local disease.
  • One patient is alive at 10 months after diagnosis with evidence of metastatic disease to bone, lungs, and breast.
  • One tumor was focally positive for keratins and EMA.
  • Spindle cell RMS is a rare neoplasm in adults and appears to have distinct clinicopathologic features when compared with cases occurring in the pediatric population.

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16006807.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Actins; 0 / Desmin; 0 / Glial Fibrillary Acidic Protein; 0 / Mucin-1; 0 / Myogenic Regulatory Factors; 0 / Myoglobin; 0 / S100 Proteins; 0 / myogenic factor 6; 68238-35-7 / Keratins; EC 3.6.4.1 / Myosins
  •  go-up   go-down






Advertisement